Northwest Biotherapeutics (NWBO) Short term Debt (2016 - 2025)
Historic Short term Debt for Northwest Biotherapeutics (NWBO) over the last 15 years, with Q3 2025 value amounting to $9.7 million.
- Northwest Biotherapeutics' Short term Debt rose 513.43% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 513.43%. This contributed to the annual value of $9.6 million for FY2024, which is 424.47% up from last year.
- Northwest Biotherapeutics' Short term Debt amounted to $9.7 million in Q3 2025, which was up 513.43% from $9.1 million recorded in Q2 2025.
- Northwest Biotherapeutics' 5-year Short term Debt high stood at $341.9 million for Q1 2021, and its period low was $7.6 million during Q2 2024.
- Its 5-year average for Short term Debt is $78.0 million, with a median of $9.6 million in 2024.
- As far as peak fluctuations go, Northwest Biotherapeutics' Short term Debt soared by 272394.68% in 2021, and later plummeted by 9143.06% in 2023.
- Over the past 5 years, Northwest Biotherapeutics' Short term Debt (Quarter) stood at $106.8 million in 2021, then decreased by 24.56% to $80.6 million in 2022, then tumbled by 88.59% to $9.2 million in 2023, then increased by 4.24% to $9.6 million in 2024, then rose by 0.91% to $9.7 million in 2025.
- Its Short term Debt was $9.7 million in Q3 2025, compared to $9.1 million in Q2 2025 and $9.5 million in Q1 2025.